In vitro-in vivo evaluation of supercritical processed solid dispersions: Permeability and viability assessment in Caco-2 cells

Journal of Pharmaceutical Sciences

Volumn 93, Issue 12, 2004, Pages 2985-2993

  Sethia, Sundeep ^a   Squillante, Emilio ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Bioavailability; Caco 2 cells; Carbamazepine; in vitro in vivo correlation; Mechanism of absorption; Solid dispersion; Supercritical fluids; TPGS

Indexed keywords

ALPHA TOCOPHEROL; CARBAMAZEPINE; DRUG CARRIER; GELUCIRE; GLYCOPROTEIN P; MACROGOL; TOCOFERSOLAN;

AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISPERSION; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; EVALUATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; SOLID STATE;

EID: 10644274441     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20199     Document Type: Article

References (30)

1. Löbenberg R, Amidon GL. 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50:3-12.
2. Moneghini M, Kikic I, Voinovich D, Perissutti B, Filipovic-Grcic J. 2001. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution. Int J Pharm 222:129-138.
3. Beach S, Latham D, Sidgwick C, Hanna M, York P. 1999. Control of the physical form of salmeterol xinafoate. Org Process Res Dev 3:370-376.
4. York P. 1999. Strategies for particle design using supercritical fluid technologies. Pharm Sci Tech Today 2:430-440.
5. Gallagher PM, Coffey MP, Krukonis VJ, Klasutis N. 1989. Gas antisolvent recrystallization: A new process to recrystallize compounds in supercritical fluids. Am Chem Soc Symp Ser 406:334-354.
6. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
7. Dintaman JM, Silverman JA. 1999. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550-1556.
8. Khoo SM, Porter CJH, Charman WN. 2000. The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment. Int J Pharm 205:65-78.
9. Rustichelli C, Gamberini G, Ferioli V, Gamberini MC, Ficarra R, Tommasini S. 2000. Solid-state study of polymorphic drugs: carbamazepine. J Pharm Biomed Anal 23:41-54.
10. Bertillson L. 1978. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 3:128-143.
11. Attia MA, Habib FS. 1985. Dissolution rates of carbamazepine and nitrazepam utilizing sugar solid dispersion system. Drug Dev Ind Pharm 11:1957-1969.
12. El-Zein H, Riad L, Abd El-Bary A. 1998. Enhancement of carbamazepine dissolution: In vitro and in vivo evaluation. Int J Pharm 168:209-220.
13. Sethia S, Squillante E. 2002. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm Sci 91:1948-1957.
14. Hidalgo IJ, Raub TJ, Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
15. Hosoya KI, Kim KJ, Lee VH. 1996. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm Res 13:885-890.
16. Hilgers AR, Conradi RA, Burton PS. 1990. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7:902-910.
17. Cory AH, Owen TC, Barltrop JA, Cory JG. 1991. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3:207-212.
18. Upton RA. 1975. Simple and reliable method for serial sampling of blood from rats. J Pharm Sci 64:112-114.
19. Sawchuk RJ, Cartier LL. 1982. Simultaneous liquid-chromatographic determination of carbamazepine and its epoxide metabolite in plasma. Clin Chem 28:2127-2130.
20. Karlsson J, Arturson P. 1992. A new diffusion chamber system for the determination of drug permeability coefficients across the human intestinal epithelium that are independent of the unstirred water layer. Biochim Biophys Acta 1111:204-210.
21. Mayersohn M, Gibaldi M. 1966. New method of solid-state dispersion for increasing dissolution rates. J Pharm Sci 55:1323-1324.
22. Nogami H, Nagai T, Suzuki A. 1966. Studies on powdered preparations. XVII. Dissolution rate of sulfonamides by rotating disk method. Chem Pharm Bull 14:329-338.
23. Kaplan SA. 1972. Biopharmaceutical considerations in drug formation design and evaluation. Drug Metab Rev 1:15-34.
24. Potschka H, Fedrowitz M, Loscher W. 2001. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12:3557-3560.
25. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. 2001. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 51:345-349.
26. Lennernäs H, Knutson L, Lesko L, Salomonson T, Amidon GL. 1995. Human effective permeability data for atenolol, metroprolol and carbamazepine to be used in the proposed biopharmaceutical classification for IR-products. Pharm Res 12:8-295.
27. Boulenc X, Roques C, Joyeux H, Berger Y, Fabre G. 1995. Bisphosphonates increases tight junction permeability in the human intestinal epithelial (Caco-2) model. Int J Pharm 123:13-24.
28. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 89:429-442.
29. Krasavage WJ, Terhaar CJ. 1977. D-α-tocopheryl polyethylene glycol 1000 succinate. Acute toxicity, subchronic feeding, reproduction and teratologic studies in the rat. Agric Food Chem 25:273-278.
30. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, Coffin M. 1999. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 16:1812-1817.